Latanoprost or Brimonidine as Treatment for Elevated Intraocular Pressure
Authors:
- Carl B CamrasCCCarl B Camras
- Wang-Pui SheuWSWang-Pui Sheu
- 1 April 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 14 (2) , 161-167
Abstract
To compare the efficacy and tolerability of latanoprost or brimonidine in patients with elevated intraocular pressure (IOP). This prospective, randomized, masked-evaluator, parallel-group, multicenter study in the United States included patients with primary open angle glaucoma or ocular hypertension. Patients received latanoprost 0.005% once daily (8:00 AM; n = 152) or brimonidine tartrate 0.2% twice daily (8:00 AM and 8:00 PM; n = 151). Patients underwent evaluation at screening, baseline (randomization), and after 0.5, 3, and 6 months of treatment. IOP was measured at 8:00 AM, 10:00 AM, noon, and 4:00 PM at baseline and the months 3 and 6 visits, and at 8:00 AM only at week 2. The main outcome measure was the difference in diurnal IOP change from baseline to month 6 between treatment groups. Adverse events were recorded at each visit. Baseline mean diurnal IOP levels were similar between groups. At month 6, the adjusted mean (+/- SEM) diurnal IOP reduction was 5.7 +/- 0.3 mm Hg in the latanoprost group and 3.1 +/- 0.3 mm Hg in patients receiving brimonidine (P < 0.001). The mean difference in diurnal IOP reduction was 2.5 +/- 0.3 mm Hg (95% CI: 1.9, 3.2; P < 0.001). Five times more patients receiving brimonidine than latanoprost were withdrawn from the study due to adverse events. Latanoprost instilled once daily is more effective and better tolerated than brimonidine administered twice daily for the treatment of patients with glaucoma or ocular hypertension. During therapy, the range of daily fluctuation of IOP is less for latanoprost compared with brimonidine.Keywords
This publication has 30 references indexed in Scilit:
- Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patientsAmerican Journal of Ophthalmology, 1999
- Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertensionOphthalmology, 1998
- A 1-Year Study of Brimonidine Twice Daily in Glaucoma and Ocular HypertensionArchives of Ophthalmology (1950), 1997
- Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertensionSurvey of Ophthalmology, 1996
- A Comparison of Latanoprost and Timolol in Primary Open-angle Glaucoma and Ocular HypertensionArchives of Ophthalmology (1950), 1996
- A Six-month, Randomized, Double-masked Study Comparing Latanoprost with Timolol in Open-angle Glaucoma and Ocular HypertensionOphthalmology, 1996
- Comparison of Latanoprost and Timolol in Patients with Ocular Hypertension and GlaucomaOphthalmology, 1996
- Effects on Intraocular Pressure and Side Effects of 0.005% Latanoprost Applied Once Daily, Evening or MorningOphthalmology, 1995
- Effects of Brimonidine on Aqueous Humor Dynamics in Human EyesArchives of Ophthalmology (1950), 1995
- Effects of PhXA41, A New Prostaglandin F2α Analog, on Aqueous Humor Dynamics in Human EyesOphthalmology, 1993